Devices Personnel

 News Release - February 22, 2006

Cardiac Science Strengthens Senior Executive Team

Key Executives to Lead Marketing, Regulatory Affairs, Accounting Teams

BOTHELL, Wash., Feb. 22 (HSMN NewsFeed) -- Cardiac Science Corporation (Nasdaq: CSCX ), a global leader in advanced cardiac monitoring and defibrillation products, today announced that it has named Garry Norris, Cheryl Shea and Daphne Taylor to its senior executive staff to strengthen its marketing, regulatory affairs/quality assurance and accounting departments.

"The combined expertise of these talented new members will allow us to enhance our competitive strengths, customer service and market-leading activities, and represents a significant investment in the future of our company," said Cardiac Science CEO John Hinson. "Their contributions will be essential in driving Cardiac Science toward further growth and success."

Garry Norris - Vice President, Marketing

As Vice President, Marketing, Garry Norris leads the global direction, execution and management of all marketing activities.

With more than 20 years of global marketing experience including product and brand marketing, marketing communications, strategic alliances and sales operations, Norris has a track record of successfully managing marketing activities to drive revenue growth, market share and brand equity in highly competitive situations.

Prior to joining Cardiac Science, Norris served as global vice president and chief marketing officer at Eastman Kodak's Health Imaging Division, where he led a series of strategic marketing initiatives that resulted in significant operational improvements and increased market share. Norris also served as director of product and brand marketing for that company's Health Imaging Division and vice president and chief marketing officer for the Consumer Imaging Division, Latin American Region.

Earlier, Norris had an extensive career at IBM, which spanned more than 18 years. He served as director of global product and brand marketing at IBM's Networking Hardware Division, where he led marketing efforts and held global responsibility for shaping the marketing direction of the division. Norris also held other marketing and sales roles while at IBM, including director, software strategy and strategic alliances and director, Microsoft Business Alliance Team.

Norris earned an MBA, Marketing and Finance, from Duke University and a Bachelor of Science, Accounting, from the University of South Carolina.

Cheryl Shea - Vice President, Regulatory Affairs & Quality Assurance

As Vice President, Regulatory Affairs & Quality Assurance, Cheryl Shea is responsible for all regulatory and quality assurance activities relating to Cardiac Science's products and services.

Shea's extensive background includes several key positions with global leaders such as Baxter Healthcare, Ohmeda and Arthocare. Her experience includes international registrations, regulatory strategy, quality systems development, clinical trial development, protocol development and execution and FDA compliance.

Prior to joining Cardiac Science, Shea owned and operated a firm providing consulting services to medical device companies. Previously she served as vice president of regulatory affairs, clinical and quality at several companies, including Cofirma and CryoGen, Inc. Earlier in her career she was director of regulatory affairs, clinical and quality at ArthroCare and also held regulatory affairs positions at Ohmeda, Baxter Healthcare and Retroperfusion, Inc.

Shea also has 12 years of experience in critical care nursing. She holds an active nursing license in the states of California and Washington, and has a public health certification in California. In addition, Shea received a Bachelor of Science, Nursing from California State University, Fullerton.

Daphne Taylor - Vice President, Corporate Controller

As Vice President, Corporate Controller, Daphne Taylor is responsible for all activities of Cardiac Science's accounting team.

Taylor has more than 15 years of experience in accounting and financial matters. Previously, she served as vice president and corporate controller at LookSmart, a publicly held software and technology company, where she managed international financial operations and led the company's project to ensure compliance with Sarbanes-Oxley.

Taylor also held corporate controller positions at SpeedTrak Communications and ViroLogic, and accounting positions at companies including Core-Mark International, Pacific Telesis Group and Coopers & Lybrand.

Taylor is a Certified Public Accountant and earned a Bachelor of Arts, Management and Accounting, from Sonoma State University.

About Cardiac Science Corporation

Cardiac Science Corporation develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators, electrocardiographs, stress test systems, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, patient monitor-defibrillators and cardiology data management systems. Cardiac Science Corporation also sells a variety of related products and consumables, and provides a comprehensive portfolio of training, maintenance and support services.

The company is the successor to various entities that have owned and operated cardiology-related businesses, which sold products under the trusted brand names Burdick®, Powerheart®, and Quinton®. Cardiac Science Corporation is headquartered in Bothell, WA, and also has operations in Lake Forest, California, Deerfield, Wisconsin, Shanghai, China, Copenhagen, Denmark and Manchester, United Kingdom.

Forward Looking Statements

This press release contains forward-looking statements. The words "believe," "expect," "intend," anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks are more fully described in the registration statement on Form S-4/A that was filed by Cardiac Science Corporation under the name CSQ Holding Company on July 28, 2005, under the caption "Risk Factors," and in the Annual Reports of Quinton Cardiology Systems, Inc. and Cardiac Science, Inc. on Form 10-K for the year ended December 31, 2004, under the captions "Certain Factors that May Affect Future Results" and in other documents, we file with the Securities and Exchange Commission. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.

Source: Cardiac Science

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.